Example, when $ZETA pulled back previously, revenue, FCF, and guidance were all stepping higher. Price was down, business was up. That is a candidate for adds. If growth is slowing and dilution is rising, that is exit territory.

Capital-intensive medtech is where ROIC mistakes get punished. $TMDX is building an integrated organ-transplant network, devices and logistics, not just selling boxes. This is how I think about whether the heavy capex ultimately earns its keep.

A concentrated portfolio guarantees this feeling: you open your screen and a core name is down 40% from highs. Is this a gift or a giant red flag? Here’s how I actually work through that

Most investors say “moat” when they really mean “stock I hope goes up.” This is laziness. Sloppy moat thinking is lethal. If $IREN, $SYM or $LMND are 5-10 year partners, you need to know what protects their cash flows, not just that they’re in hot themes like AI or automation.

My latest $ZETA chart analysis:

Execution Alert: 3 trading days Left. On Jan 2nd, I am officially rebalancing the portfolio for 2026. The Move: Selling $APP (35x NTM Sales) / Buying $IREN (9x NTM Sales). The 'Efficiency Gap' is closing. If you wait for the Q1 filings, you will be chasing the institutions (again). See the full Jan Allocation Plan: foliotrail.com/subscribe_202…

I am preparing to liquidate 16% of my portfolio. Including my two biggest winners of 2025 $APP and $TMDX . Most investors 'let winners run' until they crash. Operators rotate capital when the 'Efficiency Gap' closes. Here is my 2026 Execution Plan. 🧵